Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.

Biotechnology

Manufacturing

Oxford Biomedica Solutions

Tim Kelly

Ryan Dickerson

Melissa P.

Kelly Quesada

Volker Glidden

Stephen Boyd

Marissa Stanvick

Diane Golebiowski

David Hamilton

Lori Karpes

Amy P.

Patricia Daggett

The Director Team at Oxford Biomedica Solutions comprises leaders overseeing various critical functions such as downstream manufacturing, drug product sciences, finance and accounting, AAV platform development, CMC portfolio management, brand and marketing, warehouse operations, engineering, and facilities operations. This team ensures the strategic alignment and operational excellence needed to support the company's innovative manufacturing capabilities and collaborative approach in advancing cell and gene therapies.

Director Team

Research and Development

Quality Control and Assurance Team

Director Team

About

Team members

Other teams at Oxford Biomedica Solutions

Research and Development

Quality Control and Assurance Team